194 related articles for article (PubMed ID: 18677542)
21. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
Mikhitarian K; Pollen M; Zhao Z; Shyr Y; Merchant NB; Parikh A; Revetta F; Washington MK; Vnencak-Jones C; Shi C
Mod Pathol; 2014 May; 27(5):665-74. PubMed ID: 24186143
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
[TBL] [Abstract][Full Text] [Related]
24. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.
Agoff SN; Crispin DA; Bronner MP; Dail DH; Hawes SE; Haggitt RC
Mod Pathol; 2001 Mar; 14(3):139-46. PubMed ID: 11266517
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.
Zenali M; Overman MJ; Rashid A; Broaddus RB; Wang H; Katz MH; Fleming JB; Abbruzzese JL; Wang H
Hum Pathol; 2013 Dec; 44(12):2792-8. PubMed ID: 24139211
[TBL] [Abstract][Full Text] [Related]
28. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.
McCarthy DM; Hruban RH; Argani P; Howe JR; Conlon KC; Brennan MF; Zahurak M; Wilentz RE; Cameron JL; Yeo CJ; Kern SE; Klimstra DS
Mod Pathol; 2003 Mar; 16(3):272-8. PubMed ID: 12640108
[TBL] [Abstract][Full Text] [Related]
29. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions.
Deftereos G; Finkelstein SD; Jackson SA; Ellsworth EM; Krishnamurti U; Liu Y; Silverman JF; Binkert CR; Ujevich BA; Mohanty A
Mod Pathol; 2014 Apr; 27(4):594-601. PubMed ID: 24051700
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
31. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
33. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.
Lee JH; Giovannetti E; Hwang JH; Petrini I; Wang Q; Voortman J; Wang Y; Steinberg SM; Funel N; Meltzer PS; Wang Y; Giaccone G
Clin Cancer Res; 2012 Jan; 18(2):524-33. PubMed ID: 22128300
[TBL] [Abstract][Full Text] [Related]
34. Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia.
Bagci P; Andea AA; Basturk O; Jang KT; Erbarut I; Adsay V
Mod Pathol; 2012 Mar; 25(3):439-48. PubMed ID: 22056954
[TBL] [Abstract][Full Text] [Related]
35. Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas.
Gonzalez RS; Bagci P; Basturk O; Reid MD; Balci S; Knight JH; Kong SY; Memis B; Jang KT; Ohike N; Tajiri T; Bandyopadhyay S; Krasinskas AM; Kim GE; Cheng JD; Adsay NV
Mod Pathol; 2016 Nov; 29(11):1358-1369. PubMed ID: 27469329
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
[TBL] [Abstract][Full Text] [Related]
37. Periampullary adenocarcinoma: analysis of 5-year survivors.
Yeo CJ; Sohn TA; Cameron JL; Hruban RH; Lillemoe KD; Pitt HA
Ann Surg; 1998 Jun; 227(6):821-31. PubMed ID: 9637545
[TBL] [Abstract][Full Text] [Related]
38. Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis.
Scarpa A; Di Pace C; Talamini G; Falconi M; Lemoine NR; Iacono C; Achille A; Baron A; Zamboni G
Gut; 2000 Jun; 46(6):842-8. PubMed ID: 10807898
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
40. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
